vs
EPR PROPERTIES（EPR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是EPR PROPERTIES的1.1倍（$207.3M vs $182.9M），EPR PROPERTIES净利率更高（36.6% vs -62.0%，领先98.6%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 3.2%），EPR PROPERTIES自由现金流更多（$269.2M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.6%）
EPR地产（前身为娱乐地产信托）是总部位于美国密苏里州堪萨斯城的房地产投资信托企业，专注投资游乐园、电影院、滑雪度假村等娱乐类地产项目，截至2022年共持有353处物业。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EPR vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $182.9M | $207.3M |
| 净利润 | $66.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 56.8% | -54.7% |
| 净利率 | 36.6% | -62.0% |
| 营收同比 | 3.2% | 25.9% |
| 净利润同比 | 897.0% | 3.5% |
| 每股收益（稀释后） | $0.80 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $182.9M | $207.3M | ||
| Q3 25 | $182.3M | $159.9M | ||
| Q2 25 | $178.1M | $166.5M | ||
| Q1 25 | $175.0M | $139.3M | ||
| Q4 24 | $177.2M | $164.6M | ||
| Q3 24 | $180.5M | $139.5M | ||
| Q2 24 | $173.1M | $147.0M | ||
| Q1 24 | $167.2M | $108.8M |
| Q4 25 | $66.9M | $-128.6M | ||
| Q3 25 | $66.6M | $-180.4M | ||
| Q2 25 | $75.6M | $-115.0M | ||
| Q1 25 | $65.8M | $-151.1M | ||
| Q4 24 | $-8.4M | $-133.2M | ||
| Q3 24 | $46.6M | $-133.5M | ||
| Q2 24 | $45.1M | $-131.6M | ||
| Q1 24 | $62.7M | $-170.7M |
| Q4 25 | 56.8% | -54.7% | ||
| Q3 25 | 53.5% | -106.9% | ||
| Q2 25 | 62.5% | -64.8% | ||
| Q1 25 | 58.1% | -102.6% | ||
| Q4 24 | 25.5% | -74.3% | ||
| Q3 24 | 51.4% | -94.6% | ||
| Q2 24 | 45.9% | -79.1% | ||
| Q1 24 | 58.8% | -151.9% |
| Q4 25 | 36.6% | -62.0% | ||
| Q3 25 | 36.5% | -112.8% | ||
| Q2 25 | 42.5% | -69.0% | ||
| Q1 25 | 37.6% | -108.5% | ||
| Q4 24 | -4.7% | -80.9% | ||
| Q3 24 | 25.8% | -95.7% | ||
| Q2 24 | 26.1% | -89.5% | ||
| Q1 24 | 37.5% | -156.8% |
| Q4 25 | $0.80 | $-1.28 | ||
| Q3 25 | $0.79 | $-1.81 | ||
| Q2 25 | $0.91 | $-1.17 | ||
| Q1 25 | $0.78 | $-1.57 | ||
| Q4 24 | $-0.19 | $-1.34 | ||
| Q3 24 | $0.53 | $-1.40 | ||
| Q2 24 | $0.51 | $-1.52 | ||
| Q1 24 | $0.75 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.6M | $421.0M |
| 总债务越低越好 | $2.9B | — |
| 股东权益账面价值 | $2.3B | $-80.0M |
| 总资产 | $5.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.26× | — |
8季度趋势，按日历期对齐
| Q4 25 | $90.6M | $421.0M | ||
| Q3 25 | $13.7M | $202.5M | ||
| Q2 25 | $13.0M | $176.3M | ||
| Q1 25 | $20.6M | $127.1M | ||
| Q4 24 | $22.1M | $174.0M | ||
| Q3 24 | $35.3M | $150.6M | ||
| Q2 24 | $33.7M | $480.7M | ||
| Q1 24 | $59.5M | $112.3M |
| Q4 25 | $2.9B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $2.8B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $2.9B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.8B | — |
| Q4 25 | $2.3B | $-80.0M | ||
| Q3 25 | $2.3B | $9.2M | ||
| Q2 25 | $2.3B | $151.3M | ||
| Q1 25 | $2.3B | $144.2M | ||
| Q4 24 | $2.3B | $255.0M | ||
| Q3 24 | $2.4B | $346.8M | ||
| Q2 24 | $2.4B | $432.4M | ||
| Q1 24 | $2.4B | $140.3M |
| Q4 25 | $5.7B | $1.5B | ||
| Q3 25 | $5.5B | $1.2B | ||
| Q2 25 | $5.6B | $1.3B | ||
| Q1 25 | $5.5B | $1.3B | ||
| Q4 24 | $5.6B | $1.5B | ||
| Q3 24 | $5.7B | $1.5B | ||
| Q2 24 | $5.6B | $1.6B | ||
| Q1 24 | $5.7B | $1.3B |
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 1.23× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 1.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $421.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $269.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | 147.1% | -48.6% |
| 资本支出强度资本支出/营收 | 82.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 6.29× | — |
| 过去12个月自由现金流最近4个季度 | $568.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $421.0M | $-99.8M | ||
| Q3 25 | $136.5M | $-91.4M | ||
| Q2 25 | $87.3M | $-108.3M | ||
| Q1 25 | $99.4M | $-166.5M | ||
| Q4 24 | $393.1M | $-79.3M | ||
| Q3 24 | $122.0M | $-67.0M | ||
| Q2 24 | $78.7M | $-77.0M | ||
| Q1 24 | $99.5M | $-190.7M |
| Q4 25 | $269.2M | $-100.8M | ||
| Q3 25 | $132.1M | $-92.7M | ||
| Q2 25 | $82.4M | $-110.7M | ||
| Q1 25 | $84.7M | $-167.8M | ||
| Q4 24 | $129.2M | $-79.5M | ||
| Q3 24 | $121.5M | $-68.6M | ||
| Q2 24 | $71.3M | $-79.0M | ||
| Q1 24 | $65.0M | $-193.9M |
| Q4 25 | 147.1% | -48.6% | ||
| Q3 25 | 72.5% | -58.0% | ||
| Q2 25 | 46.3% | -66.5% | ||
| Q1 25 | 48.4% | -120.5% | ||
| Q4 24 | 72.9% | -48.3% | ||
| Q3 24 | 67.3% | -49.2% | ||
| Q2 24 | 41.2% | -53.7% | ||
| Q1 24 | 38.9% | -178.2% |
| Q4 25 | 82.9% | 0.5% | ||
| Q3 25 | 2.4% | 0.8% | ||
| Q2 25 | 2.7% | 1.5% | ||
| Q1 25 | 8.4% | 1.0% | ||
| Q4 24 | 148.9% | 0.1% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 4.2% | 1.4% | ||
| Q1 24 | 20.6% | 3.0% |
| Q4 25 | 6.29× | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.62× | — | ||
| Q2 24 | 1.74× | — | ||
| Q1 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPR
| Experiential Reportable Operating Segment | $173.3M | 95% |
| Education Reportable Operating Segment | $9.5M | 5% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
